Kintegral Advisory LLC Sells 1,044 Shares of ResMed Inc. (NYSE:RMD)

Kintegral Advisory LLC lessened its stake in shares of ResMed Inc. (NYSE:RMD - Free Report) by 32.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,129 shares of the medical equipment provider's stock after selling 1,044 shares during the period. Kintegral Advisory LLC's holdings in ResMed were worth $477,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Global X Japan Co. Ltd. lifted its position in shares of ResMed by 121.4% in the 1st quarter. Global X Japan Co. Ltd. now owns 124 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 68 shares in the last quarter. Colonial Trust Co SC increased its holdings in shares of ResMed by 6,250.0% in the 4th quarter. Colonial Trust Co SC now owns 127 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 125 shares during the period. Optiver Holding B.V. purchased a new stake in shares of ResMed in the fourth quarter worth approximately $33,000. Golden State Wealth Management LLC lifted its position in shares of ResMed by 384.8% in the first quarter. Golden State Wealth Management LLC now owns 160 shares of the medical equipment provider's stock worth $36,000 after purchasing an additional 127 shares in the last quarter. Finally, Itau Unibanco Holding S.A. boosted its holdings in shares of ResMed by 1,000.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 165 shares of the medical equipment provider's stock worth $38,000 after purchasing an additional 150 shares during the period. 54.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. UBS Group cut their target price on shares of ResMed from $290.00 to $285.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Wall Street Zen cut ResMed from a "buy" rating to a "hold" rating in a research note on Saturday, May 24th. JPMorgan Chase & Co. increased their price objective on ResMed from $286.00 to $290.00 and gave the stock an "overweight" rating in a report on Thursday, April 24th. KeyCorp set a $274.00 target price on shares of ResMed in a research report on Thursday, April 24th. Finally, Mizuho set a $265.00 price target on ResMed in a research report on Wednesday, April 16th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, ResMed currently has an average rating of "Moderate Buy" and an average price target of $259.33.

Insider Buying and Selling

In other ResMed news, Director Witte Jan De sold 2,000 shares of ResMed stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $243.47, for a total transaction of $486,940.00. Following the sale, the director directly owned 5,806 shares of the company's stock, valued at approximately $1,413,586.82. The trade was a 25.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael J. Farrell sold 8,009 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $251.21, for a total value of $2,011,940.89. Following the completion of the sale, the chief executive officer directly owned 455,503 shares in the company, valued at approximately $114,426,908.63. This represents a 1.73% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,013 shares of company stock valued at $6,863,532 over the last ninety days. 0.71% of the stock is owned by company insiders.

ResMed Stock Performance

NYSE RMD traded up $1.08 during trading on Friday, hitting $256.96. The company's stock had a trading volume of 391,893 shares, compared to its average volume of 969,821. The firm has a market cap of $37.68 billion, a P/E ratio of 28.84, a price-to-earnings-growth ratio of 1.61 and a beta of 0.77. ResMed Inc. has a 52 week low of $188.56 and a 52 week high of $263.05. The firm has a 50 day moving average price of $248.43 and a 200 day moving average price of $235.91. The company has a quick ratio of 2.49, a current ratio of 3.41 and a debt-to-equity ratio of 0.12.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.36 by $0.01. ResMed had a net margin of 26.15% and a return on equity of 25.67%. The company had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter in the previous year, the firm posted $2.13 EPS. The business's revenue was up 7.9% compared to the same quarter last year. Equities research analysts forecast that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 12th. Stockholders of record on Thursday, May 8th were issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 0.83%. The ex-dividend date of this dividend was Thursday, May 8th. ResMed's payout ratio is presently 23.79%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.